Biogen (BIIB) Reports Topline Phase 3 Results of Tofersen and its Open-Label Extension in SOD1-ALS
Go back to Biogen (BIIB) Reports Topline Phase 3 Results of Tofersen and its Open-Label Extension in SOD1-ALS| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 198.20 +1.62 (0.82%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $196.58 | 52 Week High | $333.65 | |||
| Open | $199.48 | 52 Week Low | $223.02 | |||
| Day High | $200.98 | P/E | 25.38 | |||
| Day Low | $194.74 | EPS | $7.81 | |||
| Volume | 367,166 | |||||
